Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Alimera Sciences's Total Liabilities for the quarter that ended in Dec. 2023 was $107.35 Mil. Alimera Sciences's Total Assets for the quarter that ended in Dec. 2023 was $153.52 Mil.
Therefore, Alimera Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.70.
Alimera Sciences Liabilities-to-Assets Historical Data
The historical data trend for Alimera Sciences's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alimera Sciences's Liabilities-to-Assets
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alimera Sciences's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Alimera Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Alimera Sciences Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Alimera Sciences (Alimera Sciences) Business Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALIM has been successfully added to your 